-
1Academic Journal
المؤلفون: Talukder R., Makrakis D., Lin G. I., Diamantopoulos L. N., Dawsey S., Gupta S., Carril-Ajuria L., Castellano D., de Kouchkovsky I., Jindal T., Koshkin V. S., Park J. J., Alva A., Bilen M. A., Stewart T. F., McKay R. R., Tripathi N., Agarwal N., Vather-Wu N., Zakharia Y., Morales-Barrera R., Devitt M. E., Cortellini A., Fulgenzi C. A. M., Pinato D. J., Nelson A., Hoimes C. J., Gupta K., Gartrell B. A., Sankin A., Tripathi A., Zakopoulou R., Bamias A., Murgic J., Frobe A., Rodriguez-Vida A., Drakaki A., Liu S., Lu E., Kumar V., Lorenzo G. D., Joshi M., Isaacsson-Velho P., Buznego L. A., Duran I., Moses M., Barata P., Sonpavde G., Wright J. L., Yu E. Y., Montgomery R. B., Hsieh A. C., Grivas P., Khaki A. R.
المساهمون: Talukder, R., Makrakis, D., Lin, G. I., Diamantopoulos, L. N., Dawsey, S., Gupta, S., Carril-Ajuria, L., Castellano, D., de Kouchkovsky, I., Jindal, T., Koshkin, V. S., Park, J. J., Alva, A., Bilen, M. A., Stewart, T. F., Mckay, R. R., Tripathi, N., Agarwal, N., Vather-Wu, N., Zakharia, Y., Morales-Barrera, R., Devitt, M. E., Cortellini, A., Fulgenzi, C. A. M., Pinato, D. J., Nelson, A., Hoimes, C. J., Gupta, K., Gartrell, B. A., Sankin, A., Tripathi, A., Zakopoulou, R., Bamias, A., Murgic, J., Frobe, A., Rodriguez-Vida, A., Drakaki, A., Liu, S., Lu, E., Kumar, V., Lorenzo, G. D., Joshi, M., Isaacsson-Velho, P., Buznego, L. A., Duran, I., Moses, M., Barata, P., Sonpavde, G., Wright, J. L., Yu, E. Y., Montgomery, R. B., Hsieh, A. C., Grivas, P., Khaki, A. R.
مصطلحات موضوعية: Bladder cancer, Checkpoint Inhibitor, Immunotherapy, Outcome, Platinum resistance
Relation: info:eu-repo/semantics/altIdentifier/pmid/36155169; info:eu-repo/semantics/altIdentifier/wos/WOS:000919659000016; volume:20; issue:6; firstpage:558; lastpage:567; numberofpages:10; journal:CLINICAL GENITOURINARY CANCER; https://hdl.handle.net/11579/159469; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85138769237
-
2Academic Journal
المؤلفون: Talukder R., Makrakis D., Diamantopoulos L. N., Carril-Ajuria L., Castellano D., De Kouchkovsky I., Koshkin V. S., Park J. J., Alva A., Bilen M. A., Stewart T. F., McKay R. R., Santos V. S., Agarwal N., Jain J., Zakharia Y., Morales-Barrera R., Devitt M. E., Grant M., Lythgoe M. P., Pinato D. J., Nelson A., Hoimes C. J., Shreck E., Gartrell B. A., Sankin A., Tripathi A., Zakopoulou R., Bamias A., Murgic J., Frobe A., Rodriguez-Vida A., Drakaki A., Liu S., Kumar V., Lorenzo G. D., Joshi M., Velho P. I., Buznego L. A., Duran I., Moses M., Barata P., Sonpavde G., Yu E. Y., Wright J. L., Grivas P., Khaki A. R.
المساهمون: Talukder, R., Makrakis, D., Diamantopoulos, L. N., Carril-Ajuria, L., Castellano, D., De Kouchkovsky, I., Koshkin, V. S., Park, J. J., Alva, A., Bilen, M. A., Stewart, T. F., Mckay, R. R., Santos, V. S., Agarwal, N., Jain, J., Zakharia, Y., Morales-Barrera, R., Devitt, M. E., Grant, M., Lythgoe, M. P., Pinato, D. J., Nelson, A., Hoimes, C. J., Shreck, E., Gartrell, B. A., Sankin, A., Tripathi, A., Zakopoulou, R., Bamias, A., Murgic, J., Frobe, A., Rodriguez-Vida, A., Drakaki, A., Liu, S., Kumar, V., Lorenzo, G. D., Joshi, M., Velho, P. I., Buznego, L. A., Duran, I., Moses, M., Barata, P., Sonpavde, G., Yu, E. Y., Wright, J. L., Grivas, P., Khaki, A. R.
مصطلحات موضوعية: BCG, Bladder cancer, Immunotherapy, Outcome, Urinary tract neoplasms
Relation: info:eu-repo/semantics/altIdentifier/pmid/35078711; info:eu-repo/semantics/altIdentifier/wos/WOS:000787857300019; volume:20; issue:2; firstpage:165; lastpage:175; numberofpages:11; journal:CLINICAL GENITOURINARY CANCER; https://hdl.handle.net/11579/159438; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85123348408
-
3Academic Journal
المؤلفون: Makrakis D., Talukder R., Lin G. I., Diamantopoulos L. N., Dawsey S., Gupta S., Carril-Ajuria L., Castellano D., de Kouchkovsky I., Koshkin V. S., Park J. J., Alva A., Bilen M. A., Stewart T. F., McKay R. R., Tripathi N., Agarwal N., Vather-Wu N., Zakharia Y., Morales-Barrera R., Devitt M. E., Cortellini A., Fulgenzi C. A. M., Pinato D. J., Nelson A., Hoimes C. J., Gupta K., Gartrell B. A., Sankin A., Tripathi A., Zakopoulou R., Bamias A., Murgic J., Frobe A., Rodriguez-Vida A., Drakaki A., Liu S., Lu E., Kumar V., Lorenzo G. D., Joshi M., Isaacsson-Velho P., Buznego L. A., Duran I., Moses M., Jang A., Barata P., Sonpavde G., Yu E. Y., Montgomery R. B., Grivas P., Khaki A. R.
المساهمون: Makrakis, D., Talukder, R., Lin, G. I., Diamantopoulos, L. N., Dawsey, S., Gupta, S., Carril-Ajuria, L., Castellano, D., de Kouchkovsky, I., Koshkin, V. S., Park, J. J., Alva, A., Bilen, M. A., Stewart, T. F., Mckay, R. R., Tripathi, N., Agarwal, N., Vather-Wu, N., Zakharia, Y., Morales-Barrera, R., Devitt, M. E., Cortellini, A., Fulgenzi, C. A. M., Pinato, D. J., Nelson, A., Hoimes, C. J., Gupta, K., Gartrell, B. A., Sankin, A., Tripathi, A., Zakopoulou, R., Bamias, A., Murgic, J., Frobe, A., Rodriguez-Vida, A., Drakaki, A., Liu, S., Lu, E., Kumar, V., Lorenzo, G. D., Joshi, M., Isaacsson-Velho, P., Buznego, L. A., Duran, I., Moses, M., Jang, A., Barata, P., Sonpavde, G., Yu, E. Y., Montgomery, R. B., Grivas, P., Khaki, A. R.
مصطلحات موضوعية: Advanced urothelial carcinoma, Bladder cancer, Immune checkpoint inhibitor, Metastatic cancer, Outcomes
Relation: info:eu-repo/semantics/altIdentifier/pmid/35778337; info:eu-repo/semantics/altIdentifier/wos/WOS:001043904500012; volume:20; issue:5; firstpage:440; lastpage:452; numberofpages:13; journal:CLINICAL GENITOURINARY CANCER; https://hdl.handle.net/11579/159421; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85133310824
-
4Conference
المؤلفون: Reichert, Z. R., Devitt, M. E., Alumkal, J. J., Smith, D. C., Caram, M. V., Palmbos, P., Vaishampayan, U. N., Alva, A. S., Braun, T., Yentz, S. E., Tsao, P. A., Dreicer, R., Cackowski, F. C., Shah, N., Dean, Emma J, Smith, S., Heath, E. I.
المساهمون: University of Michigan, Ann Arbor, MI
Relation: https://dx.doi.org/10.1200/JCO.2022.40.6_suppl.088; Reichert ZR, Devitt ME, Alumkal JJ, Smith DC, Caram MV, Palmbos P, et al. Targeting resistant prostate cancer, with or without DNA repair defects, using the combination of ceralasertib (ATR inhibitor) and olaparib (the TRAP trial). Vol. 40, Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2022. p. 88–88.; http://hdl.handle.net/10541/625256; Journal of Clinical Oncology
-
5Academic Journal
المؤلفون: Esagian S. M., Khaki A. R., Diamantopoulos L. N., Carril-Ajuria L., Castellano D., De Kouchkovsky I., Park J. J., Alva A., Bilen M. A., Stewart T. F., McKay R. R., Santos V. S., Agarwal N., Jain J., Zakharia Y., Morales-Barrera R., Devitt M. E., Nelson A., Hoimes C. J., Shreck E., Gartrell B. A., Sankin A., Tripathi A., Zakopoulou R., Bamias A., Rodriguez-Vida A., Drakaki A., Liu S., Kumar V., Lythgoe M. P., Pinato D. J., Murgic J., Frobe A., Joshi M., Isaacsson Velho P., Hahn N., Alonso Buznego L., Duran I., Moses M., Barata P., Galsky M. D., Sonpavde G., Yu E. Y., Msaouel P., Koshkin V. S., Grivas P.
المساهمون: Esagian, S. M., Khaki, A. R., Diamantopoulos, L. N., Carril-Ajuria, L., Castellano, D., De Kouchkovsky, I., Park, J. J., Alva, A., Bilen, M. A., Stewart, T. F., Mckay, R. R., Santos, V. S., Agarwal, N., Jain, J., Zakharia, Y., Morales-Barrera, R., Devitt, M. E., Nelson, A., Hoimes, C. J., Shreck, E., Gartrell, B. A., Sankin, A., Tripathi, A., Zakopoulou, R., Bamias, A., Rodriguez-Vida, A., Drakaki, A., Liu, S., Kumar, V., Lythgoe, M. P., Pinato, D. J., Murgic, J., Frobe, A., Joshi, M., Isaacsson Velho, P., Hahn, N., Alonso Buznego, L., Duran, I., Moses, M., Barata, P., Galsky, M. D., Sonpavde, G., Yu, E. Y., Msaouel, P., Koshkin, V. S., Grivas, P.
مصطلحات موضوعية: #uroonc, #utuc, bladder cancer, checkpoint inhibitor, immunotherapy, upper tract urothelial cancer, variant histology
وصف الملف: ELETTRONICO
Relation: info:eu-repo/semantics/altIdentifier/pmid/33556233; info:eu-repo/semantics/altIdentifier/wos/WOS:000615962100001; journal:BJU INTERNATIONAL; http://hdl.handle.net/11579/125793; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85100561925